ASCO 2019 | Patient impact: development of drugs to treat METex14 alterations

Paul Paik

Paul Paik, MD, of the Memorial Sloan Kettering Cancer Center, New York, NY, discusses how the development of drugs to treat METex14 alterations may impact lung cancer patients. This interview was recorded at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video